Algernon Pharmaceuticals Inc. (AGNPF)

Algernon Pharmaceuticals Cash Flow Statement

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 28, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020
Net Income	0.27	-0.5	-6.78	-6.05	-7.73	-8.54
Depreciation & Amortization	0.02	0.03	0.05	0.03	-	-
Loss (Gain) From Sale of Assets	-	-	-	-	-	0
Asset Writedown & Restructuring Costs	-	-	1.54	0.04	-	0.05
Stock-Based Compensation	0.06	0.29	1.26	0.53	0.83	3.18
Other Operating Activities	-1.86	-1.9	0.11	-0.05	-0.32	-0.23
Change in Accounts Receivable	0.01	0.08	0.57	1.61	-1.15	-1.12
Change in Accounts Payable	-1.37	-0.69	0.06	1.52	0.37	0.42
Change in Other Net Operating Assets	-0.02	-0.01	0.63	-0.55	0.18	-0.36
Operating Cash Flow	-2.88	-2.71	-2.55	-2.91	-7.82	-6.61
Sale (Purchase) of Intangibles	-0.08	-0.08	-0.06	-0.14	-0.12	-0.1
Other Investing Activities	2.34	2.36	-	-	-	-
Investing Cash Flow	2.26	2.28	-0.06	-0.14	-0.12	-0.1
Issuance of Common Stock	0.35	0.61	1.26	1.27	3.38	6.99
Repurchase of Common Stock	-	-	-	-	-0.31	-
Other Financing Activities	0.29	0.29	0.07	0.79	1.18	5.63
Financing Cash Flow	0.64	0.9	1.33	2.06	4.25	12.62
Foreign Exchange Rate Adjustments	0	-0	0	-0	-0.01	0
Net Cash Flow	0.02	0.47	-1.28	-1	-3.71	5.91
Free Cash Flow	-2.88	-2.71	-2.55	-2.91	-7.82	-6.61
Free Cash Flow Per Share	-0.12	-0.14	-0.17	-0.42	-1.26	-1.88
Levered Free Cash Flow	-2.5	-2.08	-0.49	-0.6	-4.69	-1
Unlevered Free Cash Flow	-2.5	-2.08	-0.49	-0.6	-4.69	-1
Change in Net Working Capital	1.56	0.87	-1.41	-2.57	0.47	1.3

Updated Jan 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.